Patents Assigned to Univ. of Texas
-
Patent number: 7576037Abstract: Apparatus and methods are described for split synthesis combinatorial chemistry that provides candidate libraries where an even distribution of theoretical products is obtainable through even mixing during the pooling step, followed by controlled redistribution of the mixed pooled products from the prior addition step into separate synthesis columns, one for each different specie of subunit to be added.Type: GrantFiled: November 18, 2005Date of Patent: August 18, 2009Assignees: MEI Technologies, Inc., Bd. of Regents, Univ. of TexasInventors: Johnnie Paul Engelhardt, David G. Gorenstein, Bruce A. Luxon
-
Patent number: 6831877Abstract: The present invention provides a system for, and method of determining an azimuth of a seismic energy source. In one embodiment, the system includes a directional assembly having a mount configured to be coupled to a seismic energy source, a rotatable mass assembly coupled to the mount, a compass rose coupled to one of the mount or the rotatable mass assembly and a direction reference coupled to the other of the mount or the rotatable mass assembly. The compass rose is registered with the direction reference to provide a direction orientation of the rotatable mass assembly with respect to the mount.Type: GrantFiled: September 14, 2001Date of Patent: December 14, 2004Assignees: Vecta Technologies, Inc., Board of Regents for the Univ. of Texas SystemInventors: Bob A. Hardage, Allen L. Gilmer
-
Publication number: 20040230334Abstract: A robotic manufacturing system may include multiple robots for transporting materials between a series of stages in a manufacturing process. To provide enhanced efficiency, each of these robots may independently operate according to a reverse process flow, cyclical schedule of operation.Type: ApplicationFiled: May 16, 2003Publication date: November 18, 2004Applicants: FSI International, Univ. of Texas at DallasInventors: H. Neil Geismar, Chelliah Sriskandarajah, Natarajan Ramanan
-
Patent number: 6562988Abstract: The present invention includes 16-HETE analogs which are agonists and antagonists of 16-HETE. The compositions may be formulated in pharmaceutically acceptable formulations. The invention also includes methods and products for inhibiting neutrophil adhesion and neutrophil aggregation using the 16-HETE agonists. One method of the invention involves the administration of a 16-HETE agonist in combination with a thrombolytic agent to a patient suffering from thromboembolic stroke.Type: GrantFiled: November 9, 2001Date of Patent: May 13, 2003Assignees: Univ. Vermont and State Agricultural College, Univ. of Texas System Board of Regents, New York Medical CollegeInventors: John R. Falck, Martin M. Bednar, Cordell E. Gross, Michael Balazy
-
Stimulation of cartilage growth with agonists of the non-proteolytically activated thrombin receptor
Publication number: 20020198154Abstract: Disclosed is a method of stimulating cartilage growth, repair or regeneration at a site in a subject in need of such growth, repair or regeneration. The method comprises the step of administering a therapeutically effective amount of an agonist of the non-proteolytically activated thrombin receptor to the site.Type: ApplicationFiled: January 16, 2002Publication date: December 26, 2002Applicant: Univ. of Texas System, Board of RegentsInventors: Darrell H. Carney, Roger S. Crowther, Janet Stiernberg, John Bergmann -
Publication number: 20020187933Abstract: The present invention relates to a method for promoting cardiac tissue repair comprising administering to the cardiac tissue a therapeutically effective amount of an angiogenic thrombin derivative peptide and/or inhibiting or reducing vascular occlusion or restenosis. The invention also relates to methods of stimulating revascularization. In yet another embodiment, the invention relates to the use of thrombin derivative peptides in the manufacture of a medicament for the methods described herein.Type: ApplicationFiled: January 16, 2002Publication date: December 12, 2002Applicant: Univ. of Texas System, Board of RegentsInventor: Darrell H. Carney
-
Publication number: 20020182205Abstract: Disclosed is a method of stimulating bone growth at a site in a subject in need of osteoinduction. The method comprises the step of administering a therapeutically effective amount of an agonist of the non-proteolytically activated thrombin receptor to the site.Type: ApplicationFiled: January 16, 2002Publication date: December 5, 2002Applicant: Univ. of Texas System, Board of RegentsInventors: Darrell H. Carney, Roger S. Crowther, David J. Simmons, Jinping Yang, William R. Redin
-
Patent number: 6040340Abstract: A method is provided for the improvement of implantation rates and/or pregnancy rates in a female mammal, comprising administering to a female mammal in whom pregnancy is desired an effective amount of(a) a nitric oxide synthase substrate, a nitric oxide donor, or both, optionally in combination with(b) a progestin, and,(c) optionally, in further combination with an estrogen.A method is also provided for fertility control for a female mammal, comprising administering to a female mammal in whom pregnancy is not desired and at risk for becoming pregnant an effective amount of nitric oxide synthase inhibitor in combination with an antiprogestin. Pharmaceutical compositions are also provided.Type: GrantFiled: May 7, 1996Date of Patent: March 21, 2000Assignees: Schering Aktiengesellschaft, The Board of Regents, Univ. of Texas SystemInventors: Krzysztof Chwalisz, Robert E. Garfield
-
Patent number: 5811233Abstract: A psoriasis susceptibility locus defined as among linked members within a family has been identified. The locus is linked to an intron of the interleukin enhancer binding factor gene in some families, while being linked to an interleukin 8 gene in other families demonstrating a familial linked form of psoriasis. The locus identified may be further defined as being located distal to genetic maker D17S784 of human chromosome 17q. This locus does not demonstrate linkage with DNA markers within flanking the HLA cluster of genes. A psoriasis susceptibility locus has also been observed close to the centromere of human chromosome 4. Both identified regions provide positive LOD scores with markers on chromosomes 17q and particularly 2 regions close to the ILF gene or the interleukin 8 gene. Methods of screening a family for psoriasis susceptibility using a defined familial psoriasis susceptibility locus are also disclosed.Type: GrantFiled: May 20, 1994Date of Patent: September 22, 1998Assignee: Board of Regents, Univ. of Texas SystemInventors: Anne Bowcock, James Tomfohrde, Alan Menter, Richard Gaynor
-
Patent number: 5785868Abstract: Sodium and borate ions are separated in supercritical water by addition of dissolved CO.sub.2 to cause precipitation of carbonates and the formation of boric acid. Carbonates and boric acid are then recovered as separate products.Type: GrantFiled: September 11, 1995Date of Patent: July 28, 1998Assignee: Board of Regents, Univ. of Texas SystemInventors: Lixiong Li, Earnest F. Gloyna
-
Patent number: 5776751Abstract: The present invention relates to a newly identified family of protein serine/threonine kinases which phosphorylate microtubule-associated protein 2 (MAP2). It is based, in part, on the cloning and characterization of novel MAP2 kinases designated extracellular signal-regulated kinase 1, 2, and 3 (ERK1, ERK2, ERK3) which are expressed in the central nervous system, and on the identification of another ERK family member, ERK4, with antisera. The present invention provides for recombinant nucleic acid molecules and proteins representing members of the MAP2 kinase family, and also for microorganisms, transgenic animals, and cell lines comprising recombinant MAP2 kinase molecules. In additional embodiments of the invention, the present invention provides for methods for assaying cellular factor activity, including, but not limited to, nerve growth factor activity, in which the activation of MAP2 kinase serves as an indicator of cellular factor activity.Type: GrantFiled: June 5, 1995Date of Patent: July 7, 1998Assignees: Regeneron Pharmaceuticals, Inc., Board of Regents, Univ Of TexasInventors: Teri G. Boulton, Melanie H. Cobb, George D. Yancopoulos, Steven Nye, Nikos Panayotatos
-
Patent number: 5678162Abstract: A mold useful for injection molding, comprising: a porous network of metal and oxidized metal and a cured epoxy resin dispersed in the porous network. The mold can be prepared by a process comprising the sequential steps of (a) forming a mixture of a metal powder and a polymer binder; (b) heating the mixture at a temperature in the range from about 100.degree. C. to about 300.degree. C. to remove a majority of the polymer binder from the mixture; (c) heating the mixture resulting from step (b) at a temperature greater than about 300.degree. C. and less than the melting point of the metal in the presence of oxygen to oxidize at least a portion of the metal to form a self-adhering porous network of metal and oxidized metal; (d) contacting the self-adhering porous network with an epoxy resin to fill at least a portion of the porous network with epoxy resin; and (e) curing the body resulting from step (d) to form the mold. The shape of the mold can be performed by selective laser sintering of the mixture.Type: GrantFiled: November 14, 1994Date of Patent: October 14, 1997Assignee: Board of Regents, Univ. of Texas SystemInventors: Joel W. Barlow, Balasubramanian Badrinarayan, Joseph J. Beaman, David L. Bourell, Richard H. Crawford, Harris L. Marcus, James R. Tobin, Neal K. Vail
-
Patent number: 5648058Abstract: The synthesis and characterization of novel molecular sieves containing bis(pentamethylcyclopentadienyl) cobalt(III) ion are described. Several types of molecular sieves were prepared using the cobalt metal complex as a template that was shown to be incorporated as a guest molecule within the molecular sieve. Molecular sieves prepared using bis(pentamethylcyclopentadienyl) cobalt(III) ion as template were characterized as having a pore size at least as large as 7 .ANG.. Other molecular sieves were also prepared using bis(cyclopentadienyl) cobalt(III) templates. The compounds are attractive as catalysts in a wide range of applications.Type: GrantFiled: May 11, 1995Date of Patent: July 15, 1997Assignee: Board of Regents, The Univ. of Texas SystemInventors: Kenneth J. Balkus, Jr., Alexi G. Gabrielov
-
Patent number: 5624636Abstract: The invention is directed to improving the disinfection of dental impressions following removal from the patient's mouth and before entering the dental laboratory to prevent contamination. It involves the use of a pH-adjusted hypochlorite solution, which is highly effective in killing microorganisms, and also relatively inexpensive. Using the solution of the instant invention for disinfection causes no damage to the impression, no loss of accuracy, and does not destroy the details on the impression surface.Type: GrantFiled: November 7, 1994Date of Patent: April 29, 1997Assignee: Univ. of Texas Board of RegentsInventor: Richard S. Schwartz
-
Patent number: 5623423Abstract: An MPEG-2 decoder circuit achieves smaller circuit area, and hence lower cost, by using circuitry, including ROMs, designed to implement residue arithmetic to calculate discrete cosine transforms in a pipelined or iterative fashion. A variable-length decoder based on ROM-like PLAs parses the stream of data to separate audio from video data and to direct the necessary operations on the data elements. The decoder and data flow through the system are controlled by a conditional MOVE processor, which is implemented as a data memory.Type: GrantFiled: December 12, 1994Date of Patent: April 22, 1997Assignee: Univ. of TexasInventor: G. Jack Lipovski
-
Patent number: 5603914Abstract: The synthesis and characterization of novel molecular sieves containing bis(pentamethylcyclopentadienyl) cobalt(III) ion are described. Several types of molecular sieves were prepared using the cobalt metal complex as a template that was shown to be incorporated as a guest molecule within the molecular sieve. Molecular sieves prepared using bis(pentamethylcyclopentadienyl) cobalt(III) ion as template were characterized as having a pore size at least as large as 7 .ANG.. Other molecular sieves were also prepared using bis(cyclopentadienyl) cobalt(III) templates. The compounds are attractive as catalysts in a wide range of applications.Type: GrantFiled: May 11, 1995Date of Patent: February 18, 1997Assignee: Board of Regents, The Univ. of Texas SystemInventors: Kenneth J. Balkus, Jr., Alexi G. Gabrielov
-
Patent number: 5595904Abstract: The present invention relates to a newly identified family of protein serine/threonine kinases which phosphorylate microtubule-associated protein 2 (MAP2). It is based, in part, on the cloning and characterization of novel MAP2 kinases designated extracellular signal-regulated kinase 1, 2, and 3 (ERK1, ERK2, ERK3) which are expressed in the central nervous system, and on the identification of another ERK family member, ERK4, with antisera. The present invention provides for recombinant nucleic acid molecules and proteins representing members of the MAP2 kinase family, and also for microorganisms, transgenic animals, and cell lines comprising recombinant MAP2 kinase molecules. In additional embodiments of the invention, the present invention provides for methods for assaying cellular factor activity, including, but not limited to, nerve growth factor activity, in which the activation of MAP2 kinase serves as an indicator of cellular factor activity.Type: GrantFiled: January 3, 1994Date of Patent: January 21, 1997Assignees: Board of Regents, Univ. of Texas, Regeneron Pharmaceuticals, Inc.Inventors: Teri G. Boulton, Melanie H. Cobb, George D. Yancopoulos, Steven Nye, Nikos Panayotatos
-
Patent number: 5580543Abstract: Texaphyrins are provided for use as radiation sensitizers. Advantageous properties of texaphyrins for use as a radiation sensitizer include: i) a low redox potential which allows radiation-induced hydrated electrons to flow to texaphyrin rather than neutralizing hydroxyl radicals, allowing hydroxyl radicals to cause cellular damage, ii) a relatively stable texaphyrin radical that reacts readily to covalently modify neighboring molecules causing further cellular damage, iii) intrinsic biolocalization, and iv) indifference to the presence or absence of O.sub.2. These properties allow texaphyrins to be particularly effective for treating the hypoxic areas of solid neoplasms. Methods of treatment for an individual having a neoplasm or atheroma include the use of a texaphyrin as a radiation sensitizer and as an agent for photodynamic tumor therapy, or the use of a texaphyrin for internal and for external ionizing radiation. Novel texaphyrins are provided.Type: GrantFiled: June 2, 1995Date of Patent: December 3, 1996Assignees: Pharmacyclics, Inc., Board of Regents, Univ. of Texas Sys.Inventors: Jonathan L. Sessler, Tarak D. Mody, Gregory W. Hemmi, Vladimir A. Kr al, Darren Magda
-
Patent number: 5565552Abstract: The invention is directed to a method of incorporating expanded porphyrins, and particularly of incorporating a sapphyrin or a texaphyrin, before, during, or after chemical synthesis of an oligomer to form an expanded porphyrin-oligonucleotide conjugate, and particularly a sapphyrin- or texaphyrin-oligonucleotide conjugate. This method includes reacting derivatized nucleotides and a sapphyrin or a texaphyrin in a desired order in an automated or manual DNA synthesizer having a solid support to form a sapphyrin- or a texaphyrin-oligonucleotide conjugate.Type: GrantFiled: June 7, 1995Date of Patent: October 15, 1996Assignees: Pharmacyclics, Inc., Board of Regents, Univ. of Texas Sys.Inventors: Darren Magda, Jonathan L. Sessler, Brent L. Iverson, Petra I. Sansom, Shaun P. Crofts
-
Patent number: 5492697Abstract: A biodegradable implant for placement in nonunion bone fractures as a substitute for bone graft material is provided which is a flat plate or disk having a thickness of between about 1 mm and about 15% of the length of the bone, interconnected micropores, and canals substantially equivalent in size and spacing to naturally-occurring Haversian canals. The implant may additionally comprise additives such as growth factors, including bone morphogenic protein. In a preferred embodiment the implant is formed from a biodegradable polymer such as a polylactic acid-polyglycolic acid copolymer by a gel casting technique followed by solvent extraction to precipitate the implant as a microporous solid.Type: GrantFiled: March 13, 1995Date of Patent: February 20, 1996Assignee: Board of Regents, Univ. of Texas SystemInventors: Barbara D. Boyan, Chandra M. Agrawal, James D. Heckman